Evaluation of a murine model of hepatic candidiasis.
A murine model of focal hepatic candidiasis which we suggest simulates certain conditions of this clinical variant of systemic candidiasis in leukemic patients is described. We have shown that outbred mice inoculated with Candida albicans by the oral-intragastric route as infants (6 days old) and then immunocompromised by cyclophosphamide and cortisone acetate treatment 2 weeks later demonstrate systemic spread of the opportunistic pathogen to the liver, lungs, spleen, and kidneys. Treatment with the immunosuppressive drugs cyclophosphamide and cortisone acetate resulted in alteration of the normal integrity of the mucosal epithelium of the gut as well as in granulocytopenia. Approximately 55% of the animals with C. albicans infections in the liver demonstrated hepatic abscesses. After these same infected, immunocompromised animals were treated with suboptimal dosages of antifungal agents (cilofungin or amphotericin B), either by intraperitoneal or subcutaneous (s.c.) routes, persistent hepatic abscesses were fewer in number and delimited by a distinct outer layer of host tissue but still contained large numbers of the viable pathogen. Blood cell counts indicated that these antifungal drug-treated animals had reestablished approximately the same number of leukocytes per microliter of blood as estimated prior to the immunocompromising drug treatment. Similar conditions in leukemic patients who were in remission and who were undergoing antifungal drug therapy for systemic candidiasis have been reported. Clearance of hepatic infections in mice was accomplished by using appropriate concentrations of amphotericin B administered by daily intraperitoneal or s.c. injection for 5 to 7 days or cilofungin by continuous s.c. infusion for 7 days. However, systemic antifungal therapy did not significantly reduce numbers of C. albicans cells in the stomach and esophagus. Persistent foci of gastrointestinal colonization by C. albicans, especially in the region of the cardial-atrium fold of the stomach of these mice, are reservoirs of the opportunistic pathogen from which reinfection may occur, leading to relapse of systemic candidiasis.
Cole
G T
GT
Department of Botany, University of Texas, Austin 78713-7640.
Lynn
K T
KT
Seshan
K R
KR
D000380:Agranulocytosis / Q000150:complications; D000666:Amphotericin B / Q000627:therapeutic use; D000818:Animals; D001835:Body Weight; D002177:Candidiasis / Q000150:complications / Q000188:drug therapy / Q000662:veterinary*; D003348:Cortisone / Q000031:analogs & derivatives / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D004195:Disease Models, Animal; D004359:Drug Therapy, Combination; D054714:Echinocandins; D004942:Esophagitis, Peptic / Q000150:complications / Q000188:drug therapy / Q000662:veterinary; D007108:Immune Tolerance; D015994:Incidence; D007275:Injections, Intravenous; D007279:Injections, Subcutaneous; D008107:Liver Diseases / Q000150:complications / Q000188:drug therapy / Q000662:veterinary*; D051379:Mice; D008826:Microbial Sensitivity Tests; D009928:Organ Specificity; D010455:Peptides / Q000008:administration & dosage / Q000627:therapeutic use; D010456:Peptides, Cyclic
D054714:Echinocandins; D010455:Peptides; D010456:Peptides, Cyclic; D000666:Amphotericin B; D003520:Cyclophosphamide; C042101:cilofungin; D003348:Cortisone